Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients

Claudia Hattinger, Serena Vella, Marilù Fanelli, Elisa Tavanti, Piero Picci, Massimo Serra

Research output: Contribution to journalReview articlepeer-review

Abstract

Second-line treatment of high-grade osteosarcoma (HGOS) patients is based on different approaches and chemotherapy protocols, which are not yet standardized. Although several drugs have been used in HGOS second-line protocols, none of them has provided fully satisfactory results and the role of rescue chemotherapy is not well defined yet. This article focuses on the drugs that have most frequently been used for second-line treatment of HGOS, highlighting the present knowledge on their mechanisms of action and resistance and on gene polymorphisms with possible impact on treatment sensitivity or toxicity. In the near future, validation of the so far identified candidate genetic biomarkers may constitute the basis for tailoring treatment by taking the patients' genetic background into account.

Original languageEnglish
Pages (from-to)2097-2114
Number of pages18
JournalPharmacogenomics
Volume17
Issue number18
DOIs
Publication statusPublished - Dec 1 2016

Keywords

  • adverse drug reactions
  • chemotherapy
  • CYP450
  • drug resistance
  • drug transporter genes
  • osteosarcoma
  • pharmacogenomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients'. Together they form a unique fingerprint.

Cite this